"10.1371_journal.pone.0017090","plos one","2011-02-24T00:00:00Z","Kerri Burgess; Tianshun Xu; Roger Brown; Bajin Han; Stephen Welle","Endocrinology and Metabolism Division, Department of Medicine, University of Rochester, Rochester, New York, United States of America; Muscle Metabolism DPU and Platform Technology and Science, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America","Conceived and designed the experiments: TX RB BH SW. Performed the experiments: KB SW. Analyzed the data: KB RB SW. Contributed reagents/materials/analysis tools: TX RB BH SW. Wrote the paper: RB SW.","GlaxoSmithKline has a potential commercial interest in the metabolic effects of reducing myostatin activity. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","02","Kerri Burgess","KB",5,TRUE,4,2,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
